In line with our findings, other groups have shown that older breast cancer patients (range 65–87 years) bearing high levels of Her2+ pre-existing T cells have low percentages of MDSCs in circulation and, more importantly, have a significant survival advantage [36]. Here, ERBB2 is linked to breast carcinoma.